In short
Tegoprubart is an innovative drug currently being studied in clinical trials for its potential to prevent kidney transplant rejection. This article explores the ongoing research on Tegoprubart, focusing on its use in kidney transplant patients and its comparison to standard immunosuppressive treatments.
At a glance
- Study Type
- Phase 2, multicenter, randomized, open-label, active control study
- Participants
- Approximately 120 de novo kidney transplant recipients
- Treatment Arms
- 1) Tegoprubart 20 mg/kg IV every 21 days; 2) Twice daily oral tacrolimus
- Common Treatments
- rATG induction, corticosteroid maintenance, mycophenolate
- Primary Endpoint
- Mean estimated glomerular filtration rate (eGFR) at 12 months
- Key Secondary Endpoints
- - Rate of graft functional impairment at 12 months; - Rate of new onset diabetes after transplant (NODAT) at 12 months; - Patient and graft survival at 12 months; - Rate of biopsy proven acute rejection (BPAR) at 12 months
- Eligibility
- Adults (≥18 years) receiving first kidney transplant, meeting specific health criteria
- Study Duration
- 12 months post-transplant (with possibility of extension)
What is Tegoprubart?
Tegoprubart, also known as AT-1501, is a new drug being studied for use in kidney transplant patients. It is designed to help prevent the body from rejecting a transplanted kidney, a condition known as renal allograft rejection. This drug is currently in the early stages of clinical trials, which means it is being tested to determine its safety and effectiveness in humans.
How Does Tegoprubart Work?
Tegoprubart is a type of drug called a monoclonal antibody. Specifically, it is a humanized IgG1k antibody that targets a protein called CD40L. CD40L plays a role in the immune system's response to foreign substances, including transplanted organs. By targeting CD40L, tegoprubart aims to prevent the immune system from attacking the new kidney, potentially improving the chances of a successful transplant.
Current Research: The BESTOW Study
The main study currently investigating tegoprubart is called BESTOW (AT-1501-K207). This is a Phase 2 clinical trial, which means it's testing the drug in a larger group of people to see how well it works and to further evaluate its safety. Here are some key points about the study:
- It's a randomized, open-label study comparing tegoprubart to another drug called tacrolimus, which is currently used to prevent organ rejection.
- The study aims to enroll about 120 people who are receiving their first kidney transplant.
- Participants will be randomly assigned to receive either tegoprubart or tacrolimus, along with other standard medications used after kidney transplants.
- The main goal is to see how well the transplanted kidney is functioning 12 months after the transplant in people who received tegoprubart compared to those who received tacrolimus.
Potential Benefits of Tegoprubart
While the full benefits of tegoprubart are still being studied, researchers hope it might offer several advantages over current treatments:
- Better kidney function: The study will measure how well the kidneys are working in people who receive tegoprubart compared to those who receive tacrolimus.
- Lower risk of rejection: Researchers will look at how many people experience rejection of their transplanted kidney with tegoprubart versus tacrolimus.
- Fewer side effects: The study will compare the safety and tolerability of tegoprubart to tacrolimus.
- Lower risk of diabetes: One of the study's goals is to see if tegoprubart leads to fewer cases of new-onset diabetes after transplant compared to tacrolimus.
- Better overall outcomes: The study will look at overall patient and kidney survival rates with tegoprubart versus tacrolimus.
Who Can Participate in the Study?
The BESTOW study has specific criteria for who can participate. Some key points include:
- Participants must be 18 years or older.
- They must be receiving their first kidney transplant from either a living or deceased donor.
- They must be willing and able to follow the study requirements, including restrictions on certain medications.
- There are also several conditions that would prevent someone from participating, such as certain medical conditions, previous organ transplants, or use of specific medications.
Study Details
The BESTOW study is divided into three main periods:
- Screening: This happens up to 28 days before the transplant.
- Transplant: This is the day of the kidney transplant surgery.
- Post-transplant Treatment: This lasts for 12 months after the transplant.
Participants will be randomly assigned to one of two groups:
- Group A will receive tegoprubart through an IV infusion every 21 days, along with other standard medications.
- Group B will receive tacrolimus twice daily by mouth, along with other standard medications.
Safety Considerations
As with any new medication, there are potential risks and side effects that are still being studied. The BESTOW trial includes several measures to monitor participants' safety:
- Regular check-ups and tests to monitor kidney function and overall health.
- Careful monitoring for side effects or adverse reactions to the medication.
- Exclusion of people with certain health conditions that might increase their risk of complications.
It's important to note that tegoprubart is still an experimental drug. While early results may be promising, more research is needed to fully understand its effectiveness and safety profile.